Alpine Immune Sciences, Inc. (ALPN)
- Previous Close
64.58 - Open
64.58 - Bid 64.51 x 400
- Ask 64.56 x 400
- Day's Range
64.50 - 64.70 - 52 Week Range
6.71 - 64.70 - Volume
3,104,151 - Avg. Volume
2,249,303 - Market Cap (intraday)
4.232B - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.64 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.50
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
www.alpineimmunesciences.comRecent News: ALPN
Performance Overview: ALPN
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALPN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALPN
Valuation Measures
Market Cap
4.23B
Enterprise Value
3.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
54.84
Price/Book (mrq)
12.91
Enterprise Value/Revenue
66.52
Enterprise Value/EBITDA
-124.70
Financial Highlights
Profitability and Income Statement
Profit Margin
-54.66%
Return on Assets (ttm)
-8.30%
Return on Equity (ttm)
-12.69%
Revenue (ttm)
58.88M
Net Income Avi to Common (ttm)
-32.18M
Diluted EPS (ttm)
-0.64
Balance Sheet and Cash Flow
Total Cash (mrq)
327.41M
Total Debt/Equity (mrq)
3.02%
Levered Free Cash Flow (ttm)
-29.06M